Product spotlight

25
Oct

Genoskin granted new patent on subcutaneous injection model

Genoskin granted a new patent on ex vivo subcutaneous injection model The French National Institute for Intellectual Property (INPI) granted Genoskin's latest patent on its unique ex vivo subcutaneous injection model, HypoSkin®. A boom in the subcutaneous biologics market Today, subcutaneous injection is one of the most common methods to deliver a drug into the human body. Its use has increased significantly
Read more
6
Sep

New study model for injectable anti-psoriasis drugs

New study model for injectable anti-psoriasis drugs A hi-tech psoriasis skin model to study drug efficacy To evaluate the efficacy of injectable anti-psoriasis drugs, the Genoskin team has designed a new test model that combines the InflammaSkin® and HypoSkin® technologies. Below you’ll find a proof-of-concept case study that illustrates the relevance of the new Hypo-InflammaSkin® model during efficacy studies of injectable
Read more
29
Mar

A unique human skin model to study subcutaneous injections

Ex vivo human skin model to predict toxicity and efficacy of subcutaneous drugs HypoSkin®: a unique ex vivo human skin model for subcutaneous injection testing Subcutaneous biologics market is an emerging area expanding at an impressive average growth rate of 7% to reach € 161 billion by 2024. To date, there is a lack of relevant in vitro biological models to
Read more
15
Feb

Genoskin develops new perfusable vascularized skin model

New ex vivo perfusable vascularized human skin model for drug testing Perfusable vascularized skin for increased viability and optimal skin response Natural human skin contains a rich vascular network, which is essential for the transport and absorption of nutrients and drugs. However, a key drawback of currently engineered human skin models is their lack in vascularization. Recreating a vascularization in
Read more
29
Sep

Genoskin launches psoriasis skin model at ESDR-meeting

Toulouse, France, September 29th, 2017 – Genoskin launches a new skin model to study skin inflammation. InflammaSkin® is a T cell-driven skin inflammation model with a psoriasis-like phenotype. The pharmacological validation of this psoriasis skin model will be presented at the 47th annual ESDR meeting 2017 (Poster 100) on September 27th to 30th, 2017. Don't hesitate to visit us in booth #9. Why immunocompetent skin
Read more
21
Sep

Study on indoor air pollution uses NativeSkin® model

New study on effects of indoor air pollution on human skin uses NativeSkin® models Indoor air pollution may alter human skin. A study that was recently published in Scientific Reports  shows that volatile organic compounds target the cellular mechanism that eliminates damaged proteins. The study uses Genoskin's NativeSkin® model to study the effects of indoor air pollution on human skin and
Read more